Contribution of neurokinin 1 receptors in the cutaneous orofacial inflammatory pain.
This study investigated the role of neurokinin 1 receptors (NK1R) in inflammatory cutaneous orofacial pain. The effects of subcutaneous and intracisternal administration of the NK1R antagonist SR140333 on the face rubbing response provoked by injection of 50 micro l of 1.5% formalin into the vibrissa pad were examined. Subcutaneous administration of SR140333 (5, 15, 30 mg/kg) induced a dose-related depressant effect on both the first and second phases of the formalin test. In contrast, intracisternal administration of SR140333 (10, 30, 60, 90 microg) produced a decrease only on the second phase with an apparent ceiling effect at approximately 50%. These data suggest that persistent nociceptive effects associated with orofacial cutaneous inflammation depend at least in part on the activation of NK1R.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002946:Cisterna Magna; D004305:Dose-Response Relationship, Drug; D005157:Facial Pain / Q000503:physiopathology*; D005557:Formaldehyde; D007249:Inflammation / Q000503:physiopathology*; D007267:Injections; D008297:Male; D064729:Neurokinin-1 Receptor Antagonists; D010147:Pain Measurement / Q000187:drug effects; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D004856:Postural Balance / Q000187:drug effects; D011812:Quinuclidines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000502:physiology*
D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; C085215:SR 140333; D005557:Formaldehyde